









Markets
/
Stocks
/
nasdaq-coll
/

Collegium Pharmaceutical Inc

COLL

36.160USD

+0.620+1.74%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.14BMarket Cap

31.45P/E TTM



Collegium Pharmaceutical Inc

36.160

+0.620+1.74%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

46 / 175

Overall Ranking

142 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

44.600

Target Price

+25.21%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 36.11% year-on-year.

Overvalued

The company’s latest PE is 31.31, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 38.21M shares, decreasing 11.94% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.23M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.09.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.67, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 188.00M, representing a year-over-year increase of 29.41%, while its net profit experienced a year-over-year increase of 38.88%.

Score

Industry at a Glance

Previous score

8.72

Change

-0.05



Financials

6.43

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.34

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.56

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.80, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 31.31, which is -9.52% below the recent high of 28.32 and 31.24% above the recent low of 21.53.

Score

Industry at a Glance

Previous score

1.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 46/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Collegium Pharmaceutical Inc is 45.00, with a high of 48.00 and a low of 40.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

44.600

Target Price

+25.49%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Collegium Pharmaceutical Inc

COLL

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.45, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 38.76 and the support level at 33.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.67

Change

-0.22

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-1.163

Neutral

RSI(14)

46.841

Neutral

STOCH(KDJ)(9,3,3)

24.992

Neutral

ATR(14)

1.286

High Vlolatility

CCI(14)

-107.112

Sell

Williams %R

71.400

Sell

TRIX(12,20)

0.117

Sell

StochRSI(14)

63.069

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

35.912

Buy

MA10

37.037

Sell

MA20

38.013

Sell

MA50

35.173

Buy

MA100

32.252

Buy

MA200

31.037

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 121.28%, representing a quarter-over-quarter increase of 1.72%. The largest institutional shareholder is The Vanguard, holding a total of 2.23M shares, representing 7.08% of shares outstanding, with 0.38% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

4.84M

-2.26%

Rubric Capital Management LP

3.00M

+27.66%

Eventide Asset Management, LLC

2.64M

+0.03%

The Vanguard Group, Inc.

Star Investors

2.24M

-1.59%

Renaissance Technologies LLC

Star Investors

1.62M

-2.74%

Principal Global Investors (Equity)

1.57M

-4.36%

Fuller & Thaler Asset Management Inc.

1.37M

+1.45%

Emerald Advisers LLC

1.40M

+1.40%

State Street Global Advisors (US)

1.38M

-4.32%

Invesco Advisers, Inc.

953.91K

-2.85%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 4.15, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.